CIAS
JAZZ icon

Capital Investment Advisory Services’s Jazz Pharmaceuticals JAZZ Stock Holding History

Capital Investment Advisory Services’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-2,475
Closed -$273K – 646
2020
Q2 		$273K Hold
2,475
– – 0.06% 257
2020
Q1 		$247K Hold
2,475
– – 0.06% 254
2019
Q4 		$369K Sell
2,475
-150
-6% -$20.4K 0.1% 202
2019
Q3 		$336K Sell
2,625
-25
-0.9% -$3.35K 0.09% 197
2019
Q2 		$354K Buy
+2,650
New +$356K 0.11% 195

Other funds holding JAZZ

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

Capital Investment Advisory Services's JAZZ Position: Q3 2020 in Review

Capital Investment Advisory Services sold out of Jazz Pharmaceuticals (JAZZ) in Q3 2020, closing a stake of 2,475 shares — an estimated $273K sold.

Capital Investment Advisory Services first reported a position in JAZZ in Q2 2019 and held it in 5 quarters. The position peaked at $369K in Q4 2019. 390 funds tracked by Wall St. Rank hold JAZZ as of Q3 2020.

  • Capital Investment Advisory Services reported no remaining Jazz Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • Capital Investment Advisory Services sold 2,475 Jazz Pharmaceuticals shares in Q3 2020, an estimated $273K.
  • Capital Investment Advisory Services first reported a position in Jazz Pharmaceuticals in Q2 2019 and held it in 5 quarters.
  • Capital Investment Advisory Services's Jazz Pharmaceuticals position peaked at $369K in Q4 2019.
  • 390 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2020.

Based on Capital Investment Advisory Services's 13F filing for Q3 2020, filed 19 Oct 2020.